Severe Anemia Ups Necrotizing Enterocolitis Risk in VLBW

This article originally appeared here.
Share this content:
Severe Anemia Ups Necrotizing Enterocolitis Risk in VLBW
Severe Anemia Ups Necrotizing Enterocolitis Risk in VLBW

TUESDAY, March 1, 2016 (HealthDay News) -- Severe anemia, but not red blood cell (RBC) transfusion, is associated with increased risk of necrotizing enterocolitis (NEC) in very low-birth-weight (VLBW) infants, according to research published in the March 1 issue of the Journal of the American Medical Association.

Ravi M. Patel, M.D., of the Emory University School of Medicine in Atlanta, and colleagues evaluated data for 598 VLBW infants (≤1,500 g) enrolled in a secondary, prospective, multicenter observational cohort study. The association between RBC transfusion, severe anemia, and NEC was assessed.

The researchers found that 44 infants (7.4 percent) developed NEC, and 319 infants (53 percent) received RBC transfusions. In the unadjusted analysis, the cumulative incidence of NEC at week eight among RBC-transfused infants was 9.9 percent, compared to 4.6 percent among nontransfused infants. In multivariable analysis, RBC transfusion in a given week was not significantly associated with the rate of NEC (adjusted cause-specific hazard ratio, 0.44; 95 percent confidence interval, 0.17 to 1.12; P = 0.09). The rate of NEC among VLBW infants with severe anemia in a given week, compared with those who did not have severe anemia, was significantly increased (adjusted cause-specific hazard ratio, 5.99; 95 percent confidence interval, 2.00 to 18.0; P = 0.001).

"Among VLBW infants, severe anemia, but not RBC transfusion, was associated with an increased risk of NEC," the authors write. "Further studies are needed to evaluate whether preventing severe anemia is more important than minimizing RBC transfusion."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »